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Strengths and limitations of this study
 Ź This study will be the irst randomised, double- blind, 
placebo- controlled trial to examine the effectiveness 
of tart cherry juice to reduce risk of recurrent gout 
lares.
 Ź Primary and secondary outcomes are central to 
treatment of gout and its comorbidities.
 Ź This study will investigate mechanisms whereby tart 
cherry juice may reduce risk of recurrent gout lares 
and comorbidities.
 Ź The study design addresses the temporal risk of gout 
lares by assessing patients over a 12- month period 
and retention of participants may be challenging.
ABSTRACT
Introduction Gout is a painful form of inlammatory 
arthritis associated with several comorbidities, particularly 
cardiovascular disease. Cherries, which are rich in anti- 
inlammatory and antioxidative bioactive compounds, are 
proposed to be eficacious in preventing and treating gout, 
but recommendations to patients are conlicting. Cherry 
consumption has been demonstrated to lower serum 
urate levels and inlammation in several small studies. 
One observational case cross- over study reported that 
cherry consumption was associated with reduced risk of 
recurrent gout attacks. This preliminary evidence requires 
substantiation. The proposed randomised clinical trial aims 
to test the effect of consumption of tart cherry juice on risk 
of gout attacks.
Methods and analysis This 12- month, parallel, 
double- blind, randomised, placebo- controlled trial 
will recruit 120 individuals (aged 18–80 years) with a 
clinical diagnosis of gout who have self- reported a gout 
lare in the previous year. Participants will be randomly 
assigned to an intervention group, which will receive 
Montmorency tart cherry juice daily for a 12- month period, 
or a corresponding placebo group, which will receive 
a cherry- lavoured placebo drink. The primary study 
outcome is change in frequency of self- reported gout 
attacks. Secondary outcome measures include attack 
intensity, serum urate concentration, fractional excretion 
of uric acid, biomarkers of inlammation, blood lipids and 
other markers of cardiovascular risk. Other secondary 
outcome measures will be changes in physical activity and 
functional status. Statistical analysis will be conducted on 
an intention- to- treat basis.
Ethics and dissemination This study has been granted 
ethical approval by the National Research Ethics Service, 
Yorkshire and The Humber—Leeds West Research Ethics 
Committee (ref: 18/SW/0262). Results of the trial will be 
submitted for publication in a peer- reviewed journal.
Trial registration number NCT03621215.
INTRODUCTION
Gout is a debilitating and common type of 
inflammatory arthritis exerting a significant 
health burden.1 2 The proportion of people 
afflicted with gout in the UK is substantial; 
around 3% of adults were affected in 2012, 
representing approximately 1.9 million 
people.3 Men are typically at greater risk 
of developing gout than women and risk 
increases with age for both genders.3 Gout 
is associated with numerous comorbidities, 
including cardiovascular disease (CVD), 
obesity and hypertension.3–5
Acute recurrent attacks of arthritis, also 
known as flares, are a defining feature of 
gout.6 The underlying cause is a build- up of 
monosodium urate crystalline deposits in the 
joints, particularly those of the lower limbs 
causing acute pain, redness and inflamma-
tion.7 8 Gout attacks are intermittent and may 
last from several days to up to several weeks. 
Usually only one joint is affected. Sustained 
hyperuricaemia, which most commonly 
occurs secondary to reduced fractional uric 
acid clearance, is recognised as the most 
important risk factor for gout.9 10 Consump-
tion of purine- rich or fructose- rich food and 
drink, including seafood, red meat, beer and 
sugar- sweetened beverages have been associ-
ated with increased uric acid levels and risk of 
gout flares.11–16
Early case reports from the 1950s suggested 
that consumption of cherries had a role to 
play in alleviating gouty pain and inflamma-
tion.17 More recently, cherries and cherry 
products have been shown to acutely lower 
serum urate after consumption in healthy 
people, while a daily supplement of cherry 
juice was associated with lower serum urate in 
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a placebo- controlled cross- over study of men and women 
who are overweight or have obesity.18–20 It is unclear 
which bioactive component in cherries may be respon-
sible for the effect; Bell et al proposed that anthocyanins 
and/or other phenolic compounds present in cherry may 
be important.18
There are very few studies in gout patients. In a case 
cross- over study of 633 gout sufferers, cherry consump-
tion was associated with a 35% lower risk of gout flares.21 
This study was predicated on an acute temporal relation-
ship between cherry consumption and likelihood of gout 
flares and did not evaluate the habitual effect of cherry 
consumption. Furthermore being observational in design, 
causality cannot be assumed.21 While there have been two 
intervention studies that have addressed the potential for 
cherry to reduce risk of gout, these were both feasibility 
studies with limited sample size, lack of an appropriate 
placebo and within- group statistical comparison.22 23
In addition to lowering serum urate, cherry consump-
tion may be of benefit in gout prophylaxis because cher-
ries contain a variety of polyphenolic compounds with 
anti- inflammatory properties. These compounds may 
ameliorate the inflammatory response induced by mono-
sodium urate crystals.18 21 Indeed, cherry consumption 
has been shown to lower a recognised biomarker of 
inflammation C- reactive protein (CRP) in both healthy 
people18 24–26 and those with arthritis.27 28
Despite the limited scientific evidence base, leading 
medical societies and charities (for example, British 
Society for Rheumatology, European League against 
Rheumatism, National Institute for Clinical Excellence, 
Arthritis Research UK, Mayo Clinic, UK Gout Society) 
endorse cherry consumption as a therapeutic aid for 
gout.1 29–33 Contrastingly, the Food and Drug Adminis-
tration in the USA has warned cherry juice growers and 
processers against making preventive disease claims.34 A 
content analysis of US and UK newspapers reported that 
25% of articles discussing dietary management of gout 
advised cherry consumption.35 Notably, the UK’s National 
Health Service health information website dismissed 
newspaper claims that advocated cherry consumption for 
gout.36 There is a clear need for definitive evidence from 
a randomised controlled trial (RCT).
The proposed study is a 12- month RCT designed to 
provide superior evidence as to whether tart cherries are 
a useful adjuvant therapy for treatment of gout. The study 
will also elucidate possible mechanisms of effect through 
the measurement of serum urate, fractional urinary urate 
excretion, biomarkers of inflammation and oxidative 
stress. As participants are likely to be at increased risk of 
CVD, secondary study outcomes will be measures of arte-
rial stiffness and blood lipids.
AIM AND OBJECTIVES
The aim of this study is to evaluate the effects of a daily 
intervention of tart cherry juice over a 12- month period 
compared with a placebo drink on risk of gout attacks.
The primary objective of this trial is to assess if a daily 
supplement of tart cherry juice influences the frequency 
of gout attacks over 12 months relative to a daily supple-
ment of a placebo drink.
Its secondary objectives are to:
 Ź Assess if tart cherry juice supplementation impacts on 
risk factors for CVD.
 Ź Identify the effects of tart cherry juice supplementa-
tion on putative biological mediators of risk of gout.
Hypotheses
 Ź In patients diagnosed with gout, a dietary interven-
tion of a daily tart cherry concentrate drink for a 
12- month period will reduce the frequency of gout 
flares compared with a placebo drink.
 Ź In patients diagnosed with gout, a dietary intervention 
of a daily tart cherry concentrate drink for a 12- month 
period will lower markers of cardiovascular risk (arte-
rial stiffness, blood pressure (BP) and blood lipids) 
compared with a placebo drink.
METHODS AND ANALYSIS
Described according to the Standard Protocol Items: 
Recommendations for Interventional Trials guidelines.37
Study design and setting
The study is a 12- month, double- blind, two- armed, 
parallel RCT performed in adults aged 18 to 80 years, 
with an existing clinical diagnosis of gout and who have 
reported at least one gout flare in the last 12 months. 
The intervention group will receive a daily supplement 
of tart cherry juice and the placebo group will receive a 
cherry- flavoured drink. The primary outcome measure 
will be between- group difference in the frequency of gout 
flares from baseline to 12 months. Secondary outcome 
measures will be between- group differences in gout 
flare pain, serum urate concentration, fractional excre-
tion of uric acid, blood lipids and recognised markers 
of inflammation (CRP, interleukin-6, tumour necrosis 
factor alpha), oxidative stress and vascular function (BP, 
arterial stiffness). Changes in physical activity, perceived 
health and pain will also be secondary outcomes. Non- 
efficacy outcomes will include dietary intake measures, 
for example total energy, total sugars and consumption of 
gout trigger foods. Each participant will be enrolled onto 
the study for 12 months; physical and vascular measure-
ments and fasted blood and 24 hours urine samples will 
be collected at 0, 6 and 12 months. These measurements 
will be made at Sheffield Hallam University's Food and 
Nutrition Research Laboratories in Sheffield, UK. Labo-
ratory visits will be postponed for any participant that is 
experiencing a gout flare until after the flare has resolved. 
An overview of the study design and timeline is given in 
figure 1. The study opened recruitment in June 2019 and 
is ongoing.
Participants and recruitment
Participants will mainly be recruited from primary care 
practices in the English city of Sheffield and surrounding 
3Lamb KL, et al. BMJ Open 2020;10:e035108. doi:10.1136/bmjopen-2019-035108
Open access
Figure 1 Participant low through the study. PA; physical activity.
areas. The Clinical Research Network of Yorkshire and 
Humber, which provides localised infrastructure to 
support delivery of research, will select practices to act 
as participant identification centres (PICs). At each PIC, 
computerised patient records will be searched to iden-
tify eligible individuals that have a clinical diagnosis of 
gout. Diagnosis is typically based on clinical examination, 
assessment of reported symptoms and elevated serum 
urate. A general practitioner will screen the list of patients 
generated from this search for suitability to participate 
(e.g. people who are frail or suffer from dementia would 
not be recruited). People who are eligible will be sent 
an invitation to participate; interested individuals will 
be encouraged to contact the research team for further 
study information. Such participants will be invited to 
attend an information, screening and enrolment meeting 
at Sheffield Hallam University. Written informed consent 
will be obtained from those willing to take part by the 
study coordinator (KL).
Recruitment from PICs will be augmented by poster 
advertising at local primary care practices and across the 
university campus, advertising on the UK Gout Society 
website and at local large- scale workplaces. Participants' 
general practitioner will be contacted to verify their 
eligibility.
Inclusion criteria
 Ź Aged between 18 and 80 years.
 Ź Clinical diagnosis of gout.
 Ź At least one self- reported gout flare with a pain 
score >3 (on a 0–10 numerical rating scale) in the past 
12 months.
 Ź Participant is able to give informed consent.
Exclusion criteria
 Ź Allergy to cherries.
 Ź Habitual consumption of cherries and/or cherry 
products.
 Ź Severe renal impairment (glomerular filtration rate 
<30 mg/L).
 Ź Type 1 or type 2 diabetes.
 Ź Recruiting practitioner deems that the patient is 
unsuitable to participate (frailty, dementia and 
terminal medical conditions).
Dietary intervention
Participants will be provided monthly with either Mont-
morency tart cherry 68 Brix concentrate (King Orchards, 
Michigan, USA) or a low- phenol, cherry- flavoured 
placebo concentrate. Both drinks will be diluted with 
water by participants before consumption (30 mL of 
concentrate with 220 mL of water, totalling 250 mL/day). 
Graduated cups with clear markings indicating required 
volumes of concentrate and water will be provided to 
participants. Participants will be advised to consume their 
drink with breakfast and to keep the concentrate refriger-
ated. Consumption will be recorded daily on a calendar. 
Advice will be given to maintain usual dietary habits 
throughout the course of the intervention and to avoid 
cherry consumption.
Each daily serving of tart cherry has been reported to 
provide: 80 kcal, 20 g carbohydrate, 870 mg phenolics and 
14 mg of anthocyanins.20 Each serving of the placebo drink 
will provide: 2.9 kcal, 0.3 g carbohydrate, 13 mg phenolics 
and 0.2 mg anthocyanins. The placebo drink has been 
constituted to have similar colour, taste and tartness as 
the cherry concentrate through the addition of blue and 
red food colourings, red and black cherry flavourings and 
citric acid to a low- fruit cordial (summer fruits flavour). It 
was not possible to match the drinks for energy content 
because the addition of sugars to the placebo drink would 
have jeopardised its shelf life. Furthermore, the addition 
of sucrose (comprising 50% fructose) has the potential to 
raise serum urate.38
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Data collection
Laboratory visit data
Anthropometric measurements
Anthropometric measures of height and weight will be 
used to calculate body mass index (weight (kg)/height2 
(m2)). Height without shoes will be measured to the 
nearest 0.1 cm using a stadiometer (Seca, Hamburg, 
Germany). Weight will be measured in light clothing to 
the nearest 0.1 kg using calibrated weighing scales (Seca 
899, Hamburg, Germany).
Fasting blood sample
Fasted venous blood samples will be collected. These will 
be analysed for: serum inflammatory markers (CRP, inter-
leukin 6 and tumour necrosis factor alpha), serum urate 
and blood lipids (total cholesterol, low- density lipopro-
tein cholesterol, high- density lipoprotein cholesterol and 
triacylglycerol). Oxidative DNA damage and antioxidant 
status will also be measured in lymphocytes using the 
Comet assay (single- cell electrophoresis).
Urine samples
Prior to each visit, participants will carry out a 24 hours 
urine collection. These samples will be used to calcu-
late 24- hour urinary uric acid excretion. A further spot 
urine sample will be collected alongside the fasting 
blood sample to calculate fractional excretion of uric 
acid.
Arterial stiffness
A Vicorder device (SMT Medical, Germany) will be used 
to measure brachial BP, central BP, carotid- femoral pulse 
wave velocity and augmentation index.
Medication use and functional status
Medication use (contemporary and historical) will be 
recorded at baseline and monitored closely throughout 
the study. This record includes both prescribed and over- 
the- counter medication. Any changes to medication use, 
for example, dosing changes or new prescriptions, will 
be recorded in the participant’s medication log. Dietary 
supplement use will also be recorded at baseline, 6 and 
12 months. Assessment of functional status covering pain, 
interference with daily activities and perceived health will 
be collected through interview using questions from a 
validated scale.39
Self-reported data
Gout lares
Information on gout flares experienced by participants 
in the preceding 12 months will be collected at baseline. 
This information covers frequency, duration, location, 
pain severity (0–10 numerical rating scale) and treatment. 
During the 12- month supplementation period, partici-
pants will keep a diary to record all instances of gouty 
pain, again covering duration, location, pain severity and 
treatment. A gout flare will be recorded if self- reported 
pain at rest is >3.40
Assessment of diet and physical activity levels
Participants will complete a 4- day food diary using esti-
mated household measures and record physical activity 
in a diary over a 4- day period in the week preceding each 
laboratory visit.
Compliance
A daily calendar will be completed to record adherence 
to the intervention. Routine monthly telephone contact 
and face- to- face contact when delivering the drinks will 
be used to encourage compliance.
Retention
Participants may withdraw from the study at any time 
without giving any reason. Reasons for discontinuing 
the study will be recorded. Participants who decide to 
discontinue the intervention will be invited to return for 
follow- up visits to assess outcome measures.
Adverse events
All adverse events (AEs) will be recorded and reported, 
where applicable, following Good Clinical Practice and 
Health Research Authority guidelines. Participants will 
be advised to report all serious or non- serious AEs to the 
research team; these data will be recorded. Additionally, 
the incidence of adverse events will be logged at labora-
tory visits and via telephone contact.
Data management
The collection and storage of data will adhere to the 
standard requirements of the EU General Data Protec-
tion Regulation 2016/679. Data will be entered onto 
electronic spreadsheets, which will be stored on a secure 
university server. All data will be treated confidentially 
and anonymised for evaluation. Hard copies of data and 
documents will be kept in a locked and secure cabinet for 
the duration of the study. Following completion of the 
study, data will be transferred to Sheffield Hallam Univer-
sity's Research Data Archive, where it will be kept for 10 
years. Hard copies will be disposed of confidentially and 
electronic data deleted after this period of time.
Randomisation, allocation and blinding
All consenting participants will be block randomised 
(block size 4) in a 1:1 allocation to either a tart cherry 
juice group or a placebo cherry- flavoured drink group 
with stratification by sex and smoking status. Allocation 
sequence will be generated using a computer random 
number generator by an investigator not involved in 
participant enrolment and data collection (AL) and 
concealed from research personnel until the comple-
tion of the trial. The study coordinator (KL) who will be 
responsible for participant enrolment, distribution of 
intervention drinks and data collection will be blinded 
to treatment allocation until results have been analysed. 
Drinks will be provided to participants in identical bottles 
and labelled with participant identification number only 
to ensure that both study coordinator and participants 
are blinded to drink allocation throughout the study.
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Sample size
The power calculation was based on the potential impact 
of tart cherry supplementation on the primary outcome 
measure. Using data on gout occurrence in UK patients, 
the chance of a recurrence of at least one gout flare over 
a 12- month period is 11%.41 It is predicted that cherry 
juice treatment will reduce this recurrence to one quarter 
of the rate of the actual recurrence (from 11% to 2.7%). 
Based on these data, it is estimated that 94 participants 
would provide 95% power at a significance level of 0.05. 
A sample of 120 participants will allow for an attrition rate 
of approximately 20%.
Statistical analysis
Continuous variables will be presented as mean and CIs. 
Statistical significance will be set at p<0.05. Descriptive 
analysis of all baseline variables will be conducted to 
compare the two groups. All analyses will be performed 
using intention- to- treat analysis; all randomised partici-
pants will be included in the final analysis as far as data 
collected will allow. Independent generalised mixed 
model analyses of variance will be performed to test for 
changes in frequency of flares from baseline to 12 months 
between treatments (cherry vs placebo); baseline, 6 
months and 12 months times will be used for secondary 
outcomes. Analysis will be performed using IBM SPSS 
Statistics version 24.0 for Windows.
Patient and public involvement
Gout patients were not directly involved in development 
of the research question or study design. We consulted 
with retired people from a local church group (Christ 
Church Fulwood, Sheffield, England) as to their under-
standing of written participant information and ques-
tionnaires. This group also provided feedback on the 
acceptability of the schedule of visits, study measures and 
intervention.
ETHICS AND DISSEMINATION
Any protocol modifications will be sent for review by the 
research ethics committee and will be amended at the trial 
registry. Participants will be sent a summary of the trial 
findings when all data have been analysed. Dissemination 
of the study findings of this study will be through publica-
tion in a leading peer- reviewed journal and presentation 
at national and international conferences.
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